The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Current Heart Failure Reports

• Publication date

  2018-02-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11897-018-0381-0PMID 29468530
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

  2017cited by this paper
• Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

  2017cited by this paper
• Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.

  2016cited by this paper
• Characterization and prediction of adverse events from intensive chronic heart failure management and effect on quality of life: results from the pro-B-type natriuretic peptide outpatient-tailored chronic heart failure therapy (PROTECT) study.

  2015cited by this paper
• Rationale and Design of the GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study

  2014cited by this paper
• Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis

  2014cited by this paper
• Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.

  2014cited by this paper
• Angiotensin-neprilysin inhibition versus enalapril in heart failure.

  2014cited by this paper
• Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management.

  2013cited by this paper
• Natriuretic Peptide-Guided Therapy in Chronic Heart Failure: A Meta-Analysis of 2,686 Patients in 12 Randomized Trials

  2013cited by this paper
• Are Serial BNP Measurements Useful in Heart Failure Management?: Serial Natriuretic Peptide Measurements Are Not Useful in Heart Failure Management The Art of Medicine Remains Long

  2013cited by this paper
• Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study.

  2013cited by this paper
• Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study

  2013cited by this paper
• Brain natriuretic peptide‐guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome

  2011cited by this paper
• The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure.

  2011cited by this paper
• Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.

  2011cited by this paper
• Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices: Primary Results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF)

  2010cited by this paper
• N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.

  2010cited by this paper
• Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study.

  2010cited by this paper
• Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.

  2009cited by this paper
• Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).

  2009cited by this paper
• N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.

  2009cited by this paper
• Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.

  2009cited by this paper
• BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.

  2009cited by this paper
• Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients.

  2008cited by this paper
• Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.

  2007cited by this paper
• Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony.

  2006cited by this paper
• Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.

  2005cited by this paper
• Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.

  2001cited by this paper
• Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.

  2000cited by this paper
• Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

  1999cited by this paper
• Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

  1996cited by this paper

• Point of Care Ultrasound (POCUS) in the Management of Heart Failure: A Narrative Review

  2024cites this paper
• 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.

  2024cites this paper
• High Soluble Suppression of Tumorigenicity-2 (sST2) is A Risk Factor for Rehospitalization and Mortality in Chronic Heart Failure Patients with Reduced Ejection Fraction

  2024cites this paper
• Biomarkers for risk stratification and antibiotic stewardship in elderly patients

  2023cites this paper
• Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction.

  2023cites this paper
• Do Heart Failure Biomarkers Influence Heart Failure Treatment Response?

  2023cites this paper
• Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists

  2023cites this paper
• Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.

  2023cites this paper
• Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society

  2023cites this paper
• Prognostic value of RDW alone and in combination with NT‐proBNP in patients with heart failure

  2022cites this paper
• Frailty and Hospitalization Burden in Patients With Chronic Heart Failure.

  2022cites this paper
• Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond

  2022cites this paper
• Point-of-care heart failure platform: where are we now and where are we going to?

  2022cites this paper
• Biomarker-Based Guideline-Directed Medical Therapy of Heart Failure: The Gap Between Guidelines and Clinical Practice

  2021cites this paper
• 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction

  2021cites this paper
• Biomarkers for the diagnosis and management of heart failure

  2021cites this paper
• Overview of the 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure With Reduced Ejection Fraction.

  2021cites this paper
• Biomarker-Based Guideline-Directed Medical Therapy of Heart Failure: The Gap Between Guidelines and Clinical Practice

  2021cites this paper
• 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.

  2021cites this paper
• Guided therapy in patients with acute heart failure: left ventricular diastolic filling pattern and NT-proBNP

  2020cites this paper
• Konzept der sequenziellen natriuretischen Peptidmessungen im Behandlungsplan der Herzinsuffizienz

  2020cites this paper
• Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register

  2019cites this paper
• Circulating Cardiac Biomarkers in Heart Failure: A Critical Link to Biomarker-Guided Therapy

  2019cites this paper
• Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week.

  2019cites this paper
• Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications

  2019cites this paper
• Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations

  2019cites this paper
• Association between admission plasma 2-oxoglutarate levels and short-term outcomes in patients with acute heart failure: a prospective cohort study

  2019cites this paper
• Heart failure drug treatment.

  2019cites this paper
• Natriuretic peptides in heart failure: Current achievements and future perspectives.

  2019cites this paper
• Established and Emerging Roles of Biomarkers in Heart Failure

  2018cites this paper
• sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.

  2018cites this paper
• Biomarkers of increased intraventricular pressure: are we ready?

  2018cites this paper